Characteristics of transplant by donor type
| . | All . | MSD . | MUD . | UCB . | dUCB . | P* . |
|---|---|---|---|---|---|---|
| Cell dose, median (range) | ||||||
| CD34+ cells, ×106 | 1 (0.01-620) | 9.6 (0.24-620) | 6.4 (0.66-380) | 0.21 (0.02-3) | 0.43 (0.01-11) | <.001† |
| Nucleated cells, ×108 | 1.7 (0.1-460) | 4.9 (0.16-320) | 5 (0.92-460) | 0.62 (0.18-30) | 0.47 (0.1-32) | <.001† |
| HLA-match, n (%) | <.001† | |||||
| 1 mismatch | 89 (28) | 0 (0) | 6 (8.2) | 53 (43) | 30 (49) | |
| >1 mismatch | 54 (17) | 0 (0) | 0 (0) | 34 (28) | 20 (33) | |
| Full match | 174 (55) | 61 (100) | 67 (92) | 35 (29) | 11 (18) | |
| Myeloablation, n (%) | <.001† | |||||
| Chemo-based‡ | 181 (57) | 46 (75) | 46 (63) | 70 (57) | 19 (31) | |
| TBI-based | 136 (43) | 15 (25) | 27 (37) | 52 (43) | 42 (69) | |
| Serotherapy, n (%) | <.001† | |||||
| No serotherapy | 212 (67) | 59 (97) | 28 (38) | 74 (61) | 51 (84) | |
| Antithymocyte globulin | 67 (21) | 1 (1.6) | 9 (12) | 47 (39) | 10 (16) | |
| Campath | 38 (12) | 1 (1.6) | 36 (49) | 1 (0.82) | 0 (0) | |
| GVHD prophylaxis, n (%) | <.001† | |||||
| CSA/MMF | 178 (56) | 21 (34) | 26 (36) | 75 (61) | 56 (92) | |
| CSA/Mtx | 87 (27) | 40 (66) | 47 (64) | 0 (0) | 0 (0) | |
| CSA/steroids | 52 (16) | 0 (0) | 0 (0) | 47 (39) | 5 (8.2) |
| . | All . | MSD . | MUD . | UCB . | dUCB . | P* . |
|---|---|---|---|---|---|---|
| Cell dose, median (range) | ||||||
| CD34+ cells, ×106 | 1 (0.01-620) | 9.6 (0.24-620) | 6.4 (0.66-380) | 0.21 (0.02-3) | 0.43 (0.01-11) | <.001† |
| Nucleated cells, ×108 | 1.7 (0.1-460) | 4.9 (0.16-320) | 5 (0.92-460) | 0.62 (0.18-30) | 0.47 (0.1-32) | <.001† |
| HLA-match, n (%) | <.001† | |||||
| 1 mismatch | 89 (28) | 0 (0) | 6 (8.2) | 53 (43) | 30 (49) | |
| >1 mismatch | 54 (17) | 0 (0) | 0 (0) | 34 (28) | 20 (33) | |
| Full match | 174 (55) | 61 (100) | 67 (92) | 35 (29) | 11 (18) | |
| Myeloablation, n (%) | <.001† | |||||
| Chemo-based‡ | 181 (57) | 46 (75) | 46 (63) | 70 (57) | 19 (31) | |
| TBI-based | 136 (43) | 15 (25) | 27 (37) | 52 (43) | 42 (69) | |
| Serotherapy, n (%) | <.001† | |||||
| No serotherapy | 212 (67) | 59 (97) | 28 (38) | 74 (61) | 51 (84) | |
| Antithymocyte globulin | 67 (21) | 1 (1.6) | 9 (12) | 47 (39) | 10 (16) | |
| Campath | 38 (12) | 1 (1.6) | 36 (49) | 1 (0.82) | 0 (0) | |
| GVHD prophylaxis, n (%) | <.001† | |||||
| CSA/MMF | 178 (56) | 21 (34) | 26 (36) | 75 (61) | 56 (92) | |
| CSA/Mtx | 87 (27) | 40 (66) | 47 (64) | 0 (0) | 0 (0) | |
| CSA/steroids | 52 (16) | 0 (0) | 0 (0) | 47 (39) | 5 (8.2) |